EyePoint Stock Hits Record Daily Low After Key Drug Failure

Key Facts

1EyePoint stock is heading for its largest single-day percentage drop on record following the failure of a key eye drug.

2The company slashed its staff significantly following the negative drug trial results.

EyePoint Pharmaceuticals stock headed for its largest single-day percentage drop on record on October 19, 2026, following the failure of a key eye drug. Barron's reported that the stock crashed below the $1 mark after the treatment failed to meet critical clinical milestones.

The company slashed its staff significantly following the negative drug trial results as part of drastic cost-cutting measures, according to Barron's. This sharp decline reflects a severe impairment in valuation and potential delisting risks following the loss of investor confidence in the company's primary pipeline.